Immutep Ltd
OTC: PRRUF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marc Voigt
- Employees
- 1,027
- Headquarters
- Sydney, Australia
- IPO year
- 2012
- Market cap
- $73.7M
- Website
- https://www.immutep.com
Loading PRRUF…
Loading profile data…Frequently asked questions about PRRUF
What does Immutep Ltd (PRRUF) do?
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of c...
Where does PRRUF trade?
Immutep Ltd (PRRUF) trades on the Other OTC.
What sector is PRRUF in?
Immutep Ltd (PRRUF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immutep Ltd?
Marc Voigt is the chief executive officer of Immutep Ltd (PRRUF).
Where is Immutep Ltd headquartered?
Immutep Ltd is headquartered in Australia.
Does PRRUF pay a dividend?
Immutep Ltd (PRRUF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PRRUF go public?
Immutep Ltd (PRRUF) completed its initial public offering in 2012.